RxDoctor Payments Data

Shirin Jaggi, DO

Hospitalist · Philadelphia, PANPI 1598292849

Payments from drug & device makers

$1,736in general payments, 2019–2025

Across 49 payments — averaging $35.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$983
  • Amarin Pharma, Inc.$212
  • Xeris Pharmaceuticals, Inc.$140
  • Insulet Corporation$139
  • Amgen$102
  • Lilly USA, LLC$42
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$1,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,736 in reported general payments places this provider in the 90th percentile of 1,287 hospitalist providers in Pennsylvania.

See all hospitalist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$115,358
Medicare patients
333
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$239,363
TrulicityDulaglutide115$185,249
MounjaroTirzepatide90$123,348
JanuviaSitagliptin Phosphate91$82,688
JardianceEmpagliflozin70$79,744
TradjentaLinagliptin53$45,349
FarxigaDapagliflozin Propanediol20$29,243
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$26,737
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$22,958
Tresiba Flextouch U-100Insulin Degludec33$19,309
Novolog FlexpenInsulin Aspart64$17,736
Lantus SolostarInsulin Glargine,hum.Rec.Anlog120$12,836
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$10,294
Nano 2nd Gen Pen NeedlePen Needle, Diabetic83$10,066
Humalog Kwikpen U-100Insulin Lispro45$6,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$42$308,597205 claims
Novo NordiskOzempic, Novolog$983$246,190168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,287 hospitalist providers in Pennsylvania.

Other hospitalist in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →